SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494500.
  • 2
    Bartynski WS. Posterior reversible encephalopathy syndrome part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008; 29: 103642.
  • 3
    Baizabal-Carvallo JF, Barragan-Campos HM, Padilla-Aranda HJ, Alonso-Juarez M, Estanol B, Cantu-Brito C, et al. Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg 2009; 111: 35963.
  • 4
    Celik M, Forta H, Turker D, Babacan G. MRI reveals reversible lesions resembling posterior reversible encephalopathy in porphyria. Neuroradiology 2002; 44: 83941.
  • 5
    Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J 2001; 77: 248.
  • 6
    King PH, Bragdon AC. MRI reveals multiple reversible cerebral lesions in an acute attack of acute intermittent porphyria. Neurology 1991; 41: 13002.
  • 7
    Shen FC, Hsieh CH, Huang CR, Lui CC, Tai WC, Chuang YC. Acute intermittent porphyria presenting as acute pancreatitis and posterior reversible encephalopathy syndrome. Acta Neurol Taiwan 2008; 17: 17783.
  • 8
    Utz N, Kinkel B, Hedde JP, Bewermeyer H. MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology 2001; 43: 105962.
  • 9
    Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology 1978; 28: 92839.
  • 10
    Fisher M, Maister B, Jacobs R. Hypertensive encephalopathy: diffuse reversible white matter CT abnormalities. Ann Neurol 1985; 18: 26870.
  • 11
    Hauser RA, Lacey DM, Knight MR. Hypertensive encephalopathy: magnetic resonance imaging demonstration of reversible cortical and white matter lesions. Arch Neurol 1988; 45: 107883.
  • 12
    Kwong YL, Yu YL, Lam KS, Woo E, Ma JT, Huang CY. CT appearance in hypertensive encephalopathy [letter]. Neuroradiology 1987; 29: 215.
  • 13
    Rail DL, Perkin GH. Computerized tomographic appearance of hypertensive encephalopathy. Arch Neurol 1980; 37: 3101.
  • 14
    Weingarten K, Barbut D, Filippi C, Zimmerman RD. Acute hypertensive encephalopathy: findings on spin-echo and gradient-echo MR imaging. AJR Am J Roentgenol 1994; 162: 66570.
  • 15
    Ergun T, Lakadamyali H, Yilmaz A. Recurrent posterior reversible encephalopathy syndrome in a hypertensive patient with end-stage renal disease. Diagn Interv Radiol 2008; 14: 1825.
  • 16
    Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, et al. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992; 159: 37983.
  • 17
    D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369: 58796.
  • 18
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 19
    Ishimori ML, Pressman BD, Wallace DJ, Weisman MH. Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE? Lupus 2007; 16: 43643.
  • 20
    Kur JK, Esdaile JM. Posterior reversible encephalopathy syndrome: an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol 2006; 33: 217883.
  • 21
    Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 98592.
  • 22
    Asherson RA, Mercey D, Phillips G, Sheehan N, Gharavi AE, Harris EN, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46: 60511.
  • 23
    Mills JA. Systemic lupus erythematosus. N Engl J Med 1994; 330: 18719.
  • 24
    Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity 2005; 38: 50718.
  • 25
    Kushner M. Lupus anticoagulants, anti-cardiolipin antibodies and cerebral ischemia. Stroke 1989; 20: 2259.
  • 26
    Vergne P, Bertin P, Bonnet C, Scotto C, Treves R. Drug-induced rheumatic disorders: incidence, prevention and management. Drug Saf 2000; 23: 27993.
  • 27
    Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142: 43950.
  • 28
    Kauppinen R. Porphyrias. Lancet 2005; 365: 24152.
  • 29
    Herrick AL, McColl KE. Acute intermittent porphyria. Best Pract Res Clin Gastroenterol 2005; 19: 23549.
  • 30
    Crimlisk HL. The little imitator—porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 1997; 62: 31928.
  • 31
    Ventura P, Deomnica MC, Rocchi E. The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Intern Emerg Med 2009; 4: 297308.
  • 32
    Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill; 1995. p. 2103.
  • 33
    Allard SA, Charles PJ, Herrick AL, McColl KE, Scott JT. Antinuclear antibodies and the diagnosis of systemic lupus erythematosus in patients with acute intermittent porphyria. Ann Rheum Dis 1990; 49: 2468.
  • 34
    Korkmaz C. Delayed diagnosis of porphyria based on manifestations of systemic lupus erythematosus and ankylosing spondylitis. J Nephrol 2006; 19: 5359.